Baebies, a diagnostic development company whose aim is to improve neonatal screening has raised $13 million in equity financing. The company, which was founded by Dr. David L. Goldfarb, the former director of pediatric neurosurgery at Johns Hopkins Hospital and an expert on fetal brain development, said it would use that money for clinical Baebies is developing a screening platform that employs microfluidics, and consists of a bench-top analyser and software that runs tests on samples in digital microfluidic cartridges.
Baebies, a diagnostic development company whose aim is to improve neonatal screening has raised $13 million in equity financing. The main investors included: Duke University, Cunning Capital, Triad and the Duke Angel Network. Baebies is developing a screening platform that employs microfluidics, and consists of a bench-top analyser and software that runs tests on samples in digital microfluidic cartridges.